CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 57 enrolled
Drug / intervention
WinterLight Mobile Phone Speech Analysisother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05563818
NCT05563818N/ACompleted

Monitoring Symptoms Severity in Arabic Speaking Schizophrenic Patients Using Mobile Phone Speech Analysis: A Proof-of-Concept Study

Hikma Pharmaceuticals LLC·observational·Posted Oct 3, 2022·Updated Sep 22, 2023

In Brief

An observational study evaluating WinterLight Mobile Phone Speech Analysis for Schizophrenia. Completed, enrolled 57 participants across 4 sites in 4 countries.

Detailed Summary

Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters. The purpose of this study is to investigate the relationship between speech features and severity of positive and negative clinical symptoms in Arabic speaking patients with schizophrenia. Individuals will be invited to participate in this study because (1) they have a confirmed clinical diagnosis of schizophrenia; (2) they plan to receive routine clinical care for schizophrenia at one of the four participating sites; (3) they speak Arabic as a first language. Participants must be between the ages of 18-65 years. Participation will involve seven visits consisting of one baseline visit and six monthly follow-up visits. All participants will continue to receive routine clinical care. Participation in this research will involve providing speech samples using standardized tasks collected using an electronic device. Additionally, study team members will assess positive and negative symptoms of schizophrenia using validated questionnaires.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesAlgeria, Egypt, Jordan, Saudi Arabia
CollaboratorsWinterlight Labs

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 3, 2022
Enrollment StartNov 9, 2021
Primary CompletionDec 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.7 years ago

Interventions

WinterLight Mobile Phone Speech Analysisother

N/A- observational study